Breast cancer distant recurrence risk assessment
myStage Dx for early breast cancer.
myStage Dx is a physician-requested test that helps assess distant recurrence risk in adults with node-positive, estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative early breast cancer. It uses information from a routine H&E pathology slide and standard clinicopathologic variables.
Healthcare providers
Review intended use, evidence, report and ordering workflow.
Access clinical evidence, sample report, implementation options, and ordering information for myStage Dx.
Patients and caregivers
Learn what myStage Dx is and how physicians interpret results.
Learn what myStage Dx is, why your doctor may order it, how your tumor slide is used, and what the results mean.